NZ596058A - Influenza hemagglutinin compositions and uses thereof - Google Patents

Influenza hemagglutinin compositions and uses thereof

Info

Publication number
NZ596058A
NZ596058A NZ596058A NZ59605810A NZ596058A NZ 596058 A NZ596058 A NZ 596058A NZ 596058 A NZ596058 A NZ 596058A NZ 59605810 A NZ59605810 A NZ 59605810A NZ 596058 A NZ596058 A NZ 596058A
Authority
NZ
New Zealand
Prior art keywords
ectodomain
hemagglutinin protein
fragment
influenza virus
virus hemagglutinin
Prior art date
Application number
NZ596058A
Other languages
English (en)
Inventor
Andrea Jegerlehner
Philippe Saudan
Martin Bachmann
Original Assignee
Cytos Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology Ag filed Critical Cytos Biotechnology Ag
Publication of NZ596058A publication Critical patent/NZ596058A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ596058A 2009-04-30 2010-04-30 Influenza hemagglutinin compositions and uses thereof NZ596058A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09159262 2009-04-30
PCT/EP2010/055944 WO2010125202A1 (en) 2009-04-30 2010-04-30 Influenza hemagglutinin compositions and uses thereof

Publications (1)

Publication Number Publication Date
NZ596058A true NZ596058A (en) 2013-08-30

Family

ID=42790940

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ596058A NZ596058A (en) 2009-04-30 2010-04-30 Influenza hemagglutinin compositions and uses thereof

Country Status (9)

Country Link
US (1) US20120263743A1 (https=)
EP (1) EP2424570A1 (https=)
JP (1) JP2012525134A (https=)
CN (1) CN102573915B (https=)
AU (1) AU2010243490A1 (https=)
CA (1) CA2759873A1 (https=)
NZ (1) NZ596058A (https=)
SG (1) SG175382A1 (https=)
WO (1) WO2010125202A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106822887A (zh) * 2017-01-26 2017-06-13 中国科学院微生物研究所 一种流感病毒四价亚单位疫苗及其应用
SG11202109850SA (en) 2019-03-13 2021-10-28 Generation Bio Co Non-viral dna vectors and uses thereof for expressing fviii therapeutics

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2327382T3 (es) * 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
DE60234375D1 (de) * 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
ES2316628T3 (es) * 2001-11-07 2009-04-16 Cytos Biotechnology Ag Disposicion ordenada de antigenos que comprende rankl para el tratamiento de enfermedades oseas.
US7138252B2 (en) * 2002-07-17 2006-11-21 Cytos Biotechnology Ag Molecular antigen arrays
RU2375076C2 (ru) * 2003-07-10 2009-12-10 Цитос Биотехнологи Аг Укомплектованные вирусоподобные частицы
CN101023103A (zh) * 2004-09-21 2007-08-22 赛托斯生物技术公司 包含ap205外壳蛋白和抗原性多肽的融合蛋白的病毒样颗粒
MX2007003171A (es) * 2004-09-21 2007-05-23 Cytos Biotechnology Ag Particulas tipo virus que comprenden una proteina de fusion de la proteina de cubierta de ap205 y un polipeptido antigenico.
US8420102B2 (en) * 2006-03-07 2013-04-16 Vaxinnate Corporation Compositions that include hemagglutinin
CA2615658A1 (en) * 2005-07-19 2007-01-25 Dow Global Technolgies Inc. Recombinant flu vaccines
AU2006279323B2 (en) * 2005-08-16 2013-08-01 Merck Sharp & Dohme Corp. Influenza recombinant subunit vaccine
KR101359723B1 (ko) * 2005-10-18 2014-02-05 노바백스, 인코포레이티드 기능성 인플루엔자 바이러스 유사 입자들
CA2636139A1 (en) * 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
CU23576A1 (es) * 2006-02-28 2010-09-30 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la influenza aviar
CN101394864A (zh) * 2006-03-07 2009-03-25 法克斯因内特公司 包含血细胞凝集素的组合物、制造其的方法与使用其的方法

Also Published As

Publication number Publication date
JP2012525134A (ja) 2012-10-22
SG175382A1 (en) 2011-12-29
EP2424570A1 (en) 2012-03-07
CN102573915A (zh) 2012-07-11
WO2010125202A1 (en) 2010-11-04
CA2759873A1 (en) 2010-11-04
CN102573915B (zh) 2015-02-18
US20120263743A1 (en) 2012-10-18
AU2010243490A1 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
WO2007011904A3 (en) Recombinant flu vaccines
WO2009026397A3 (en) Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
WO2008014521A8 (en) Improved vaccines and methods for using the same
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
EP4241785A3 (en) Influenza virus vaccines and uses thereof
TW200732476A (en) Functional influenza virus like particles (VLPs)
MX392585B (es) Particulas similares al virus de la influenza quimericas que comprenden hemaglutinina.
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
AU2014310935B2 (en) Combination vaccine
GEP20135924B (en) Chimeric viruses presenting non-native surface proteins and usage thereof
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
EA201001045A1 (ru) Модифицированный вирус гриппа
ATE552846T1 (de) Verbesserter grippeimpfstoff
EA201190327A1 (ru) Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv
MX345150B (es) Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h5n1 y h1n1.
WO2009155489A3 (en) Compositions and methods for treating influenza
HK1203524A1 (en) Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
NZ741875A (en) Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof
ZA202100386B (en) Influenza virus hemagglutinin mutants
MY163972A (en) Attenuated recombinant newcastle disease virus and vaccine containing the same
EP3599247A3 (en) Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
NZ596058A (en) Influenza hemagglutinin compositions and uses thereof
MY207280A (en) Polyvalent immunogenicity composition for human papillomavirus
MX2019007924A (es) Vacunas contra la influenza.
WO2011039180A3 (en) Novel vaccine composition against influenza

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 APR 2017 BY DENNEMEYER SA

Effective date: 20140314

LAPS Patent lapsed